Windlas Biotech Limited — Investor Meet, 21-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Windlas Biotech delivered robust Q1 FY26 results: Revenue INR 210 Cr (+20% YoY), EBITDA INR 27 Cr (+27% YoY), PAT INR 18 Cr (+31% YoY). All verticals grew, led by Exports (+45.4%). Management highlighted the 10th consecutive quarter of record revenue and optimism for the Indian pharma sector. Plant 6 refurbishment is on schedule, aiming for commercialization in FY27, contributing to a INR 1,000 Cr revenue potential (excluding injectables). Injectables expansion is contingent on reaching peak utilization. Company eyes strategic M&A or organic dosage form expansion. Management maintains a confident outlook on long-term growth.